ANKRD49 Inhibitors
ANKRD49 inhibitors are a class of chemical compounds designed to specifically target the ANKRD49 protein, which is a member of the ankyrin repeat domain-containing protein family. ANKRD49 contains several ankyrin repeat motifs, which are structural elements that facilitate protein-protein interactions. These motifs consist of repeating helix-loop-helix structures that create a stable surface for binding to other proteins. Through these interactions, ANKRD49 plays an important role in various cellular processes, such as signaling pathways, protein localization, and structural organization within the cell. ANKRD49 inhibitors are developed to block these interactions by binding to the ankyrin repeat domains, preventing ANKRD49 from forming or stabilizing protein complexes. By disrupting these interactions, the inhibitors interfere with the normal function of the protein in cellular processes that depend on ANKRD49.
The chemical diversity of ANKRD49 inhibitors is broad, with compounds ranging from small organic molecules to peptides and more complex synthetic constructs. These inhibitors are typically designed to exploit specific features of the ankyrin repeat domains, such as hydrophobic pockets or charged regions, which are essential for the binding of ANKRD49 to its partners. Some inhibitors work by mimicking the natural binding partners of ANKRD49, competitively occupying the interaction sites and thus preventing ANKRD49 from engaging in its typical protein-protein interactions. Others induce conformational changes that destabilize the ankyrin repeat domains, impairing the ability of ANKRD49 to maintain its functional structure. Through these mechanisms, ANKRD49 inhibitors provide a valuable tool for studying the molecular interactions mediated by this protein and the broader role of ankyrin repeat domains in regulating protein networks within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases. By broadly inhibiting protein kinase activity, it can disrupt downstream signaling pathways that may include those involving ANKRD47. If ANKRD47 function depends on phosphorylation events, staurosporine could inhibit its activity by preventing such modifications. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K (phosphoinositide 3-kinases). PI3K signaling is implicated in a vast array of cellular functions. Inhibition by LY294002 can lead to a reduction in AKT phosphorylation and activity, which in turn could affect cellular processes that ANKRD47 is involved in, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin), which is central to a cellular signaling pathway important for cell growth and proliferation. mTOR inhibition can affect the cytoskeletal organization, potentially affecting ANKRD47 if its function is related to cytoskeletal dynamics. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. The p38 MAPK pathway is involved in inflammatory responses and stress signaling. Inhibition of this pathway could lead to alterations in cellular stress responses, potentially affecting the functional state of ANKRD47 if it is stress-responsive. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, which in turn prevents the activation of ERK, a kinase involved in the MAPK/ERK signaling pathway. If ANKRD47 is regulated by ERK-mediated signaling, inhibition by PD98059 could reduce ANKRD47 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor, which can lead to the accumulation of misfolded proteins and subsequent cellular stress. If the function of ANKRD47 is sensitive to proteostasis, bortezomib-induced stress could inhibit its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor, limiting the activation of the ERK pathway. By inhibiting MEK, U0126 could reduce ERK activity and possibly affect the regulation of ANKRD47, assuming it is part of this signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinases), which are critical for controlling apoptosis, cytokine production, and other cellular processes. Inhibition of JNK could lead to altered cell survival signaling, potentially impacting ANKRD47 function if it is involved in these processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, like LY294002, and exerts its effects by covalently binding to the catalytic site of the enzyme. This inhibition could downregulate AKT signaling, indirectly affecting ANKRD47 if it relies on AKT-mediated pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs), which affects chromatin structure and gene expression. If the expression or activity of ANKRD47 is regulated by acetylation status, trichostatin A could lead to its inhibition. | ||||||